Eating disorders: What age at onset?

Volpe, Umberto; Tortorella, Alfonso; Manchia, Mirko; Monteleone, Alessio Maria; Albert, Umberto; Monteleone, Palmiero

doi:10.1016/j.psychres.2016.02.048

Cited by 166 publications

(115 citation statements)

References 25 publications

Supporting

Mentioning

107

Contrasting

Unclassified

Order By: Relevance

“…Second, the majority of mental health professionals do not provide care to populations and clinical problems for which there is an especially great demand (children and the elderly, individuals of minority groups, special populations in need such as victims of violence, single‐mothers, individuals of lower income). For example, most psychiatric disorders have their onset in childhood and adolescence, including eating disorders (Micali, Hagberg, Petersen, & Treasure, ; Stice, Marti, & Rohde, ; Volpe et al, ), but most individuals in the mental health professions are trained in the treatment of adults. Children's access to evidence‐based mental health treatment is an urgent matter in its own right (Garland et al, ).…”

Section: Critical Gaps In Treatmentmentioning

confidence: 99%

“…College student counseling centers are an optimal setting in which to study the implementation of evidence‐based treatment for eating disorders. These disorders typically begin in adolescence and the young adult years (Micali et al, ; Stice et al, ; Volpe et al, ), and they constitute one of the most common mental health problems seen by college counseling centers/health services (Resnick, ). In this study, several reasons dictated the choice of IPT: (1) readily acceptable to therapists and clients (National Institute for Health and Clinical Excellence, ; Tanofsky‐Kraff & Wilfley, ); (2) hypothesized to result in high rates of adoption because it is perceived as similar to the type of psychotherapy many therapists in student counseling centers provide; (3) IPT, with its focus on interpersonal issues, is particularly appropriate for a population of young adults, especially females (Weisz & Hawley, ; Wilson et al, ); (4) broadly applicable to a wide range of clients with an eating disorder (Wilson et al, ); and (5) IPT may have broader therapeutic effects than just those on eating disorders (Cuijpers et al, ; Markowitz et al, ; Weissman et al, ).…”

Section: Addressing Critical Gaps In Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Addressing critical gaps in the treatment of eating disorders

Kazdin

Fitzsimmons‐Craft

Wilfley

2017

Intl J Eating Disorders

241

221

View full text Add to dashboard Cite

Remarkable progress has been made in developing psychosocial interventions for eating disorders and other mental disorders. Two priorities in providing treatment consist of addressing the research-practice gap and the treatment gap. The research-practice gap pertains to the dissemination of evidence-based treatments from controlled settings to routine clinical care. Closing the gap between what is known about effective treatment and what is actually provided to patients who receive care is crucial in improving mental health care, particularly for conditions such as eating disorders. The treatment gap pertains to extending treatments in ways that will reach the large number of people in need of clinical care who currently receive nothing. Currently, in the United States (and worldwide), the vast majority of individuals in need of mental health services for eating disorders and other mental health problems do not receive treatment. This article discusses the approaches required to better ensure: 1) that more people who are receiving treatment obtain high-quality, evidence-based care, using such strategies as train-the-trainer, web-centered training, best-buy interventions, electronic support tools, higher-level support and policy; and 2) that a higher proportion of those who are currently underserved receive treatment, using such strategies as task shifting and disruptive innovations, including treatment delivery via telemedicine, the Internet, and mobile apps.

show abstract

Section: Critical Gaps In Treatmentmentioning

confidence: 99%

Section: Addressing Critical Gaps In Treatmentmentioning

confidence: 99%

Addressing critical gaps in the treatment of eating disorders

Kazdin

Fitzsimmons‐Craft

Wilfley

2017

Intl J Eating Disorders

241

221

View full text Add to dashboard Cite

show abstract

“…Both in AN and BN, the age range in which the debut is most common is between the ages of 15 and 19, with tendency to decrease in recent years, while for the BED it is distributed in a wider band with a peak in early adulthood [4,9]. There is, however, a significant difference between intercepted pathology and epidemiologically estimated disease, so many people with ED do not receive treatment; Additionally, those people with ED receive inappropriate care.…”

Section: Introductionmentioning

confidence: 99%

The role of endocannabinoids in the control of eating disorders

Milano¹,

Tecce²,

Capasso³

2017

Dis Disord

View full text Add to dashboard Cite

Eating Disorder (ED) is a syndrome characterized by persistent alteration of eating behavior and the conditions that cause an insufficient ingestion and/or adsorption of foods. There are three different ED diseases: Anorexia Nervosa (AN), Bulimia Nervosa (BN) and Binge Eating Disorders (BED). ED are complex conditions that arise from a combination of long-standing behavioral, emotional, psychological, interpersonal, and social factors. The neuronal circuits that control the ingestion of food are mainly related to catecholaminergic, serotoninergic and peptidergic systems. In this respect, while serotonin, dopamine and prostaglandin promote the ingestion of food, by contrast, neuropeptide Y, norepinephrine, GABA and opioid peptides inhibit food ingestion thus causing the occurrence of ED. The drugs mainly used in the treatment of ED are antidepressants such as selective serotonin reuptake inhibitors and tricyclic antidepressant. Additionally, mood stabilizers (lithium), anxiolytics, serotonin and noradrenalin reuptake inhibitors and antipsychotic drugs are often used in the treatment of ED.Several studies indicate that the endocannabinoid system is involved in ED supporting the idea that the cannabinoid signaling system is a key modulatory element in the activity in the brain area associated with ED.

show abstract

“…The aspects of hunger and of insatiable voracity are also present in the ancient Greek and Hebraic literature, such as typical and caricatural figures of the obese, of their irrepressible greediness and gluttony [1][2][3][4][5][6][7][8][9][10].…”

Section: Introductionmentioning

confidence: 99%

“…Even if know since antiquity, only recently these disorders have been object of systematic researches and studies on the psychopathological, neuroendocrinological and clinical plane; considered for a long time endocrinological or internist diseases or symptoms and variants of other nosographic sphere like hysteria, obsessive neurosis, schizophrenia or depression, the ED have today their nosographic connotation [1][2][3][4][5][6][7][8][9][10].…”

Section: Introductionmentioning

confidence: 99%